The vast majority of peptide therapeutics are not sufficiently orally bioavailable due to their lack of intrinsic ability to overcome physiological barriers. Within the BMBF (VIP+) and EKFS (Translatorik) funded project "LipOra" we are developing a novel formulation for the oral administration of peptide therapeutics based on lipophilic modified cell penetrating peptides with the lead candidate octreotide. The overall goal is to establish a platform technology for the oral administration of macromolecular drugs.